"@LOGOS" Multi-omics Salon

Dr. Michael Previte is the co-founder and CTO of Element Biosciences, with over a decade of experience in technological innovation in the field of genomics. Prior to joining Element, he served as the associate principal scientist at Illumina, leading the development of several cutting-edge sequencing platforms, and was deeply involved in the early development of single-molecule sequencing technology at Life Technologies.

He holds a Ph.D. in Physical Chemistry from Boston College and completed his postdoctoral training at MIT, with a long-term focus on combining advanced microscopic imaging with high-throughput biochemical techniques. Michael has over 25 patents in multiple technological fields such as sequencing, enzymology, instrumentation, and surface chemistry, and has published more than 35 papers. He is one of the core scientists driving the development of high-dimensional multi-omics.

Professor at the School of Life Sciences and Affiliated Cancer Hospital of Fudan University, and Director of the Shanghai International Institute for Human Phenome Research,CountryDistinguishedExpert (2010), Peak Talent of Mingzhu in Pudong New Area, Shanghai (2024), and Principal Investigator of National Key R&D Program Projects (2019 and 2023). Dedicated to ensuring high quality and reliability of multi-omics data, mining biomarkers for disease prevention, diagnosis, and treatment, to improve the success rate of new drug development and the effectiveness of clinical drug use. Co-founder of Shenzhen Chipscreen Biosciences (688321.SH), co-inventor of the Class 1.1 anti-cancer drug Chidamide and the Class 1.1 anti-diabetes drug Ciglitin Sodium; served over a decade as a senior FDA PI in the United States, initiated the international MAQC consortium for omics data quality control and an international society, with Nature Publishing Group releasing five special issues; developed the world’s first set of multi-omics reference materials, establishing a new paradigm for multi-omics measurement based on proportional quantification, addressing batch effects and integration challenges in multi-omics data; co-achieved precise molecular subtyping and targeted therapy for triple-negative breast cancer, significantly improving patient survival rates; led or participated in the formulation of five ISO standards and FDA guidelines for omics, holds 10 international invention patents, has published over 200 papers (including 20 in Nature Biotechnology), cited over 20,000 times in SCI, with an h-index of 70. Bachelor's degree in Analytical Chemistry from Hunan University (1985) and Master's degree in Computational Chemistry from the University of Science and Technology of China (1991).

In January 2019, Chen Nan received his Ph.D. in Chemical Biology from Peking University under the supervision of Professor Wang Chu. He then pursued postdoctoral research at Rockefeller University in the United States. In March 2021, he returned to China and co-founded Nanjing ChroChem Biotechnology Co., Ltd. with Professor Wang Chu, Academician Guo Zijian, and others. Since 2022, he has served as an off-campus mentor for professional degree graduate students at Nanjing University and has received support from projects such as the Jiangsu Province "Double Innovation Plan" for entrepreneurial talent.

Dr. Chen Nan has long been dedicated to the development of chemical proteomics technology and its application in small molecule drug discovery and mechanism research. His related research achievements have been published in more than 20 academic papers, with 17 domestic patents applied for (7 of which have been granted), and he also owns 2 PCT international patents.

Vice Dean of the Institute of Translational Medicine, Shanghai Jiao Tong University; Vice Dean of Xinjiang Medical Academy; Yangtze River Scholar.Distinguished Adjunct ProfessorProfessor, Shanghai UniversityDistinguished Adjunct ProfessorProfessor (Oriental Scholar), doctoral supervisor; member of the Shanghai Municipal Committee of the Chinese People's Political Consultative Conference, PI of the national key laboratory, responsible scientist of the national major scientific and technological infrastructure for translational medicine, dual-appointed professor at the affiliated hospital of the medical college; undergraduate from Fudan University, Ph.D. from the University of Queensland, visiting scholar at Stanford University; as chairman, organized multiple international academic conferences, established several academic professional committees, and was responsible for building multiple large-scale translational medicine and precision medicine mass spectrometry centers and laboratories.

Chief Scientist of the "National Key R&D Program" of the Ministry of Science and Technology, Project Leader of the National Natural Science Foundation, Leader of Shanghai's "Biomedical Field Support Plan", Leader of the Major Projects under Shanghai’s "Natural Science Research and Innovation Plan," and serves as a judge for multiple domestic and international research projects; recipient of Shanghai's "Young Science and Technology Rising Star Program" and Shanghai's "PujiangTalent Program"Recipient of the Shanghai 'Youth May 4th Medal', recipient of the Outstanding Youth Award in Experimental Medicine in China, recipient of the Ruiyuan Youth Science and Technology Award, leading a team responsible for over 40 national and Shanghai-level scientific research projects."

Serving as editorial board member or editor of 9 journals and reviewer of more than 70 journals, has published over 170 SCI papers in journals such as Cell, with a total impact factor of more than 1900, and has received awards from multiple international societies and journals; has industrialization background, applied for more than 50 patents, cooperated with many domestic and foreign biotechnology enterprises, tertiary hospitals, and medical institutions, obtained registration for more than 50 medical devices, led the team to win the Gold Award for Excellent Innovative Products in China's In Vitro Diagnostics, Special Gold Award of China University Scientific and Technological Achievements Fair, First Prize of Shanghai Technical Invention, Chinese Medical Science and Technology Award, Hua Xia Medical Science and Technology Award, etc.

The leadership team focuses on the translational medical applications of molecular group engineering, involving interdisciplinary integration of biology, materials, instrumentation, algorithms, chemistry, and medicine. Their work covers three main research directions: multi-omics interface design, intelligent detection software and hardware, and life system reprogramming, which are of significant theoretical importance and practical value. Driven by the actual needs of clinical medicine application and biological mechanism exploration, molecular group engineering has broad application prospects in the development of in vitro early diagnosis and monitoring of major diseases, and has become a highly challenging and promising interdisciplinary field.

With 16 years of experience in omics data analysis and mining, he has long focused on the translational application of proteomics and multi-omics technologies in clinical precision medicine. He has deeply participated in the design and execution of multiple high-impact research projects, cumulatively supporting clients in publishing over fifty papers in high-level international journals such as Nature Communications, Advanced Science, and EMBO Molecular Medicine.

She is familiar with the automated pre-processing workflow for large-scale proteomics data and high-performance mass spectrometry platforms, and is skilled in multidimensional data integration analysis starting from clinical issues, including proteomics, phosphoproteomics, glycoproteomics, genomics, and metabolomics. In recent years, she has successfully led and implemented several large-cohort clinical research projects, and is adept at rapidly and accurately uncovering the potential value of omics data to develop high-quality clinical application solutions.

The head of bioinformatics at Seqanza, graduated from East China Normal University, with over 10 years of experience in bioinformatics analysis. Previously served as a bioinformatics engineer at the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. Has long been responsible for the data analysis of cancer genomics, transcriptomics, and epigenomics. Conducted biomarker identification, prognostic associations, and other analyses in several large-scale cancer genomic studies. Also responsible for developing multiple bioinformatics tools, platforms, and products, possessing extensive experience in NGS data processing and applications. Collaborated with clients on esophageal cancer molecular subtyping and lung cancer heterogeneity research, with related findings published in journals such as Cancer Cell, Nature Communications, and Cell Research. Holds three published patents. Awarded the title of "Chief Technician" of Pudong New Area in 2024.